Standout Papers

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes 2016 2026 2019 2022 4.1k
  1. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (2018)
    Stephen D. Wiviott, Itamar Raz et al. New England Journal of Medicine
  2. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions (2016)
    Michael G. Silverman, Brian A. Ference et al. JAMA

Immediate Impact

8 from Science/Nature 87 standout
Sub-graph 1 of 13

Citing Papers

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
2024 Standout
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
2024 Standout
3 intermediate papers

Works of Michael G. Silverman being referenced

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes
2019
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
2016 Standout

Author Peers

Author Last Decade Papers Cites
Michael G. Silverman 1924 2556 431 4282 42 6.5k
Julia Kuder 3030 3409 171 4736 59 8.4k
Matthew A. Cavender 2280 2025 336 4558 83 6.5k
Robert P. Byington 3930 2905 520 6470 53 11.0k
Thomas A. Zelniker 2385 2725 128 6545 67 8.4k
David Preiss 2052 3180 296 4176 103 8.1k
KyungAh Im 1493 1440 124 3380 47 4.5k
Eri Kato 1916 2396 74 5783 45 7.2k
Jacob A. Udell 3000 2305 291 5196 158 8.4k
Gérald Luc 2947 3067 178 2544 87 8.9k
Hanna E. Bloomfield 2002 4601 200 3767 81 8.3k

All Works

Loading papers...

Rankless by CCL
2026